J Dig Cancer Res.  2022 Jun;10(1):9-15. 10.52927/jdcr.2022.10.1.9.

Long Term Proton Pump Inhibitor Use and Gastric Cancer

• Seo SI

• KMID: 2530343
• DOI: http://doi.org/10.52927/jdcr.2022.10.1.9

Abstract

Proton pump inhibitors (PPIs), a potent gastric acid inhibitor, are widely used in gastric acidrelated diseases such as gastroesophageal reflux disease and peptic ulcer, and are known as the most frequently used drugs worldwide. However, as the frequency of use increases, the number of cases of long-term PPI therapy without clear indications is increasing. Recently, there have been concerns about the risk of gastric cancer in patients with long-term PPI users. Potential mechanisms for the association between PPI and gastric cancer include enterochromaffin-like cell proliferation due to hypergastrinemia caused by gastric acid suppression, progression of atrophic gastritis, and corpus-predominant type through interaction with Helicobacter pylori (H. pylori) infection. Several epidemiologic studies showed controversial results on the issue, and it is difficult to prove a causal relationship between PPI and gastric cancer. Nevertheless, long-term PPI should be administered cautiously based on individual risk-benefit profile, specifically among those with history of H. pylori infection, in high-risk region of gastric cancer.

Keyword

Proton pump inhibitors; Gastric cancer

Reference

1. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. 1995; The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol. 35:277–305. DOI: 10.1146/annurev.pa.35.040195.001425. PMID: 7598495. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0028926928&origin=inward.

2. Savarino V, Tosetti C, Benedetto E, Compare D, Nardone G. 2018; Appropriateness in prescribing PPIs: a position paper of the Italian Society of Gastroenterology (SIGE) - Study section "Digestive Diseases in Primary Care". Dig Liver Dis. 50:894–902. DOI: 10.1016/j.dld.2018.07.004. PMID: 30093304. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85050957927&origin=inward.

3. Freedberg DE, Kim LS, Yang YX. 2017; The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 152:706–715. DOI: 10.1053/j.gastro.2017.01.031. PMID: 28257716. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85014357803&origin=inward.

4. Vaezi MF, Yang YX, Howden CW. 2017; Complications of proton pump inhibitor therapy. Gastroenterology. 153:35–48. DOI: 10.1053/j.gastro.2017.04.047. PMID: 28528705. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016476376&origin=inward.

5. Joo MK, Park JJ, Chun HJ. 2019; Proton pump inhibitor: the dual role in gastric cancer. World J Gastroenterol. 25:2058–2070. DOI: 10.3748/wjg.v25.i17.2058. PMID: 31114133. PMCID: PMC6506576. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85065887173&origin=inward.

6. Tatsuguchi A, Hoshino S, Kawami N, et al. 2020; Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa. Pathol Res Pract. 216:153113. DOI: 10.1016/j.prp.2020.153113. PMID: 32853950. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85088041759&origin=inward.

7. Fossmark R, Martinsen TC, Waldum HL. 2019; Adverse effects of proton pump inhibitors-evidence and plausibility. Int J Mol Sci. 20:5203. DOI: 10.3390/ijms20205203. PMID: 31640115. PMCID: PMC6829383. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073761995&origin=inward.

8. Havu N. 1986; Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 35 Suppl 1:42–55. DOI: 10.1159/000199381. PMID: 3792671. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84940635220&origin=inward.

9. Poynter D, Pick CR, Harcourt RA, et al. 1985; Association of long lasting unsurmountable histamine H₂ blockade and gastric carcinoid tumours in the rat. Gut. 26:1284–1295. DOI: 10.1136/gut.26.12.1284. PMID: 2867954. PMCID: PMC1433126. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0022394794&origin=inward.

10. Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. 2011; Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut. 60:624–630. DOI: 10.1136/gut.2010.207662. PMID: 21097844. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79953732352&origin=inward.

11. McCarthy DM. 2020; Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids-what is the relationship? Int J Mol Sci. 21:662. DOI: 10.3390/ijms21020662. PMID: 31963924. PMCID: PMC7014182. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85078254225&origin=inward.

12. Bakkelund K, Fossmark R, Nordrum I, Waldum H. 2006; Signet ring cells in gastric carcinomas are derived from neuroendocrine cells. J Histochem Cytochem. 54:615–621. DOI: 10.1369/jhc.5A6806.2005. PMID: 16344325. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33646688705&origin=inward.

13. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. 2015; Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 42:649–663. DOI: 10.1111/apt.13324. PMID: 26177572. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84939562887&origin=inward.

14. Freedberg DE, Lebwohl B, Abrams JA. 2014; The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 34:771–785. DOI: 10.1016/j.cll.2014.08.008. PMID: 25439276. PMCID: PMC4254461. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84923922666&origin=inward.

15. Imhann F, Bonder MJ, Vich Vila A, et al. 2016; Proton pump inhibitors affect the gut microbiome. Gut. 65:740–748. DOI: 10.1136/gutjnl-2015-310376. PMID: 26657899. PMCID: PMC4853569. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84954286591&origin=inward.

16. Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. 2017; The gastric and intestinal microbiome: role of proton pump inhibitors. Curr Gastroenterol Rep. 19:42. DOI: 10.1007/s11894-017-0577-6. PMID: 28733944. PMCID: PMC5621514. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85025434230&origin=inward.

17. Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrügger RW. 2001; Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 15:379–388. DOI: 10.1046/j.1365-2036.2001.00888.x. PMID: 11207513. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035115434&origin=inward.

18. Labenz J, Tillenburg B, Peitz U, et al. 1996; Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology. 110:725–732. DOI: 10.1053/gast.1996.v110.pm8608881. PMID: 8608881. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0030044363&origin=inward.

19. Sanduleanu S, Jonkers D, De Bruïne A, Hameeteman W, Stockbrügger RW. 2001; Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther. 15:1163–1175. DOI: 10.1046/j.1365-2036.2001.01029.x. PMID: 11472319. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0034920472&origin=inward.

20. Brusselaers N, Wahlin K, Engstrand L, Lagergren J. 2017; Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 7:e017739. DOI: 10.1136/bmjopen-2017-017739. PMID: 29084798. PMCID: PMC5665226. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85032688694&origin=inward.

21. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. 2018; Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 67:28–35. DOI: 10.1136/gutjnl-2017-314605. PMID: 29089382. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85039850298&origin=inward.

22. Liu P, McMenamin ÚC, Johnston BT, et al. 2020; Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. Br J Cancer. 123:307–315. DOI: 10.1038/s41416-020-0860-4. PMID: 32367073. PMCID: PMC7374738. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85085099070&origin=inward.

23. Niikura R, Hayakawa Y, Hirata Y, Yamada A, Fujishiro M, Koike K. 2018; Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut. 67:1908–1910. DOI: 10.1136/gutjnl-2017-315710. PMID: 29273641. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047375273&origin=inward.

24. Poulsen AH, Christensen S, McLaughlin JK, et al. 2009; Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 100:1503–1507. DOI: 10.1038/sj.bjc.6605024. PMID: 19352380. PMCID: PMC2694435. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=65549096192&origin=inward.

25. Seo SI, Park CH, You SC, et al. 2021; Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut. 70:2066–2075. DOI: 10.1136/gutjnl-2020-323845. PMID: 33975868. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85106014323&origin=inward.

26. Shin GY, Park JM, Hong J, Cho YK, Yim HW, Choi MG. 2021; Use of proton pump inhibitors vs histamine 2 receptor antagonists for the risk of gastric cancer: population-based cohort study. Am J Gastroenterol. 116:1211–1219. DOI: 10.14309/ajg.0000000000001167. PMID: 34074826. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85107404752&origin=inward.

27. Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. 2022; Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 71:16–24. DOI: 10.1136/gutjnl-2021-325097. PMID: 34226290. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85109262595&origin=inward.

28. García Rodríguez LA, Lagergren J, Lindblad M. 2006; Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 55:1538–1544. DOI: 10.1136/gut.2005.086579. PMID: 16785284. PMCID: PMC1860118. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33750352352&origin=inward.

29. Lee JK, Merchant SA, Schneider JL, et al. 2020; Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a community-based population. Am J Gastroenterol. 115:706–715. DOI: 10.14309/ajg.0000000000000591. PMID: 32205645. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089522176&origin=inward.

30. Tamim H, Duranceau A, Chen LQ, Lelorier J. 2008; Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study. Drug Saf. 31:675–684. DOI: 10.2165/00002018-200831080-00004. PMID: 18636786. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=47649114119&origin=inward.

31. Song H, Zhu J, Lu D. 2014; Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. (12):CD010623. DOI: 10.1002/14651858.CD010623.pub2. PMID: 25464111. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84925226708&origin=inward.

32. Segna D, Brusselaers N, Glaus D, Krupka N, Misselwitz B. 2021; Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therap Adv Gastroenterol. 14:17562848211051463. DOI: 10.1177/17562848211051463. PMID: 34777575. PMCID: PMC8586163. PMID: 924dd09202ec453aaa541906d990a963. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85118957866&origin=inward.

33. Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. el-Omar EM. 1995; Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology. 109:681–691. DOI: 10.1016/0016-5085(95)90374-7. PMID: 7657096. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0029149571&origin=inward.

34. Kuipers EJ, Uyterlinde AM, Peña AS, et al. 1995; Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 90:1401–1406. PMID: 7661157. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0029146892&origin=inward.

35. Uemura N, Okamoto S, Yamamoto S, et al. 2001; Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–789. DOI: 10.1056/NEJMoa001999. PMID: 11556297. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035856021&origin=inward.

36. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. 1996; Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 334:1018–1022. DOI: 10.1056/NEJM199604183341603. PMID: 8598839. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=15844369552&origin=inward.

37. Schenk BE, Kuipers EJ, Nelis GF, et al. 2000; Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut. 46:615–621. DOI: 10.1136/gut.46.5.615. PMID: 10764703. PMCID: PMC1727929. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0034065646&origin=inward.

38. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. 2004; Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 53:12–20. DOI: 10.1136/gut.53.1.12. PMID: 14684569. PMCID: PMC1773939. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=9144272432&origin=inward.

39. Malfertheiner P, Megraud F, O'Morain CA, et al. 2017; Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 66:6–30. DOI: 10.1136/gutjnl-2016-312288. PMID: 27707777. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84991677089&origin=inward.

40. Targownik LE, Fisher DA, Saini SD. 2022; AGA Clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 162:1334–1342. DOI: 10.1053/j.gastro.2021.12.247. PMID: 35183361. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85124762889&origin=inward.